Johnson & Johnson (JNJ) — Upcoming Catalysts

FDA PDUFA dates, advisory-committee meetings, and Phase 2/3 readout windows for Johnson & Johnson, built from public data lanes (ClinicalTrials.gov and official sources). Each row links to its source.

For informational purposes only — not investment advice. Track JNJ live on Mooboard →

Next 30 days2

  • Oct 12, 2026
    Johnson & Johnson(JNJ)Phase 2/3 readout
    Apalutamide · Phase 3 · Metastatic Castrate-sensitive Prostate Cancer
    NCT05884398: A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC. Primary completion 2026-10-12 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Oct 15, 2026
    Johnson & Johnson(JNJ)Phase 2/3 readout
    Milvexian · Phase 3 · Ischemic Stroke; Ischemic Attack, Transient
    NCT05702034: A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE. Primary completion 2026-10-15 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗

31–90 days4

  • Nov 19, 2026
    Johnson & Johnson(JNJ)Phase 2/3 readout
    JNJ-95597528 · Phase 2 · Dermatitis, Atopic
    NCT07230860: A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis. Primary completion 2026-11-19 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Dec 1, 2026
    Johnson & Johnson(JNJ)Phase 2/3 readout
    Apalutamide · Phase 3 · Prostatic Neoplasms
    NCT03767244: A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy. Primary completion 2026-12-01 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Dec 8, 2026
    Johnson & Johnson(JNJ)Phase 2/3 readout
    Milvexian · Phase 3 · Atrial Fibrillation
    NCT05757869: A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation. Primary completion 2026-12-08 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Dec 22, 2026
    Johnson & Johnson(JNJ)Phase 2/3 readout
    JNJ-64042056 · Phase 2 · Alzheimer Disease
    NCT06544616: A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease. Primary completion 2026-12-22 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗

Later19

  • Dec 30, 2026
    Johnson & Johnson(JNJ)Phase 2/3 readout
    Seltorexant · Phase 3 · Depressive Disorder, Major
    NCT06559306: Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms. Primary completion 2026-12-30 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Dec 30, 2026
    Johnson & Johnson(JNJ)Phase 2/3 readout
    Cetrelimab · Phase 3 · Urinary Bladder Neoplasms
    NCT04658862: A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder. Primary completion 2026-12-30 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Dec 31, 2026
    Johnson & Johnson(JNJ)Phase 2/3 readout
    Ibrutinib · Phase 3 · Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
    NCT01804686: A Long-term Extension Study of PCI-32765 (Ibrutinib). Primary completion 2026-12-31 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Jan 31, 2027
    Johnson & Johnson(JNJ)Phase 2/3 readout
    Cetrelimab · Phase 1 / Phase 2 · Carcinoma, Non-Small-Cell Lung
    NCT05908734: A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer. Primary completion 2027-01-31 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Feb 10, 2027
    Johnson & Johnson(JNJ)Phase 2/3 readout
    Icotrokinra · Phase 3 · Arthritis, Psoriatic
    NCT06807424: A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis. Primary completion 2027-02-10 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Feb 10, 2027
    Johnson & Johnson(JNJ)Phase 2/3 readout
    Guselkumab Subcutaneous · Phase 3 · Colitis, Ulcerative
    NCT06260163: A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis. Primary completion 2027-02-10 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Feb 26, 2027
    Johnson & Johnson(JNJ)Phase 2/3 readout
    JNJ-68284528 · Phase 2 · Multiple Myeloma
    NCT04133636: A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma. Primary completion 2027-02-26 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Feb 26, 2027
    Johnson & Johnson(JNJ)Phase 2/3 readout
    Bleximenib · Phase 1 / Phase 2 · Acute Leukemia
    NCT04811560: A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1). Primary completion 2027-02-26 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Mar 25, 2027
    Johnson & Johnson(JNJ)Phase 2/3 readout
    Guselkumab · Phase 3 · Fistulizing Crohns Disease; Perianal Crohns Disease
    NCT05347095: A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease. Primary completion 2027-03-25 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Apr 27, 2027
    Johnson & Johnson(JNJ)Phase 2/3 readout
    Amivantamab IV · Phase 1 / Phase 2 · Advanced or Metastatic Colorectal Cancer
    NCT05379595: A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer. Primary completion 2027-04-27 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Apr 28, 2027
    Johnson & Johnson(JNJ)Phase 2/3 readout
    Capmatinib · Phase 1 / Phase 2 · Carcinoma, Non-Small-Cell Lung
    NCT05488314: A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer. Primary completion 2027-04-28 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • May 14, 2027
    Johnson & Johnson(JNJ)Phase 2/3 readout
    Nipocalimab · Phase 2 / Phase 3 · Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
    NCT05327114: Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Primary completion 2027-05-14 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • May 31, 2027
    Johnson & Johnson(JNJ)Phase 2/3 readout
    Amivantamab IV · Phase 2 · Carcinoma, Non-Small-Cell Lung
    NCT06120140: Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib. Primary completion 2027-05-31 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Jun 8, 2027
    Johnson & Johnson(JNJ)Phase 2/3 readout
    Guselkumab · Phase 3 · Crohn's Disease
    NCT06408935: Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients. Primary completion 2027-06-08 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Jun 14, 2027
    Johnson & Johnson(JNJ)Phase 2/3 readout
    JNJ-79635322 · Phase 2 · Multiple Myeloma
    NCT07266441: A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma. Primary completion 2027-06-14 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Jun 28, 2027
    Johnson & Johnson(JNJ)Phase 2/3 readout
    JNJ-88545223 · Phase 2 · Arthritis, Psoriatic
    NCT07321873: A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis. Primary completion 2027-06-28 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Jun 30, 2027
    Johnson & Johnson(JNJ)Phase 2/3 readout
    Nipocalimab · Phase 2 / Phase 3 · Myasthenia Gravis
    NCT05265273: A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis. Primary completion 2027-06-30 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Jun 30, 2027
    Johnson & Johnson(JNJ)Phase 2/3 readout
    Talquetamab · Phase 2 · Hematological Malignancies
    NCT04634552: A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma. Primary completion 2027-06-30 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Jun 30, 2027
    Johnson & Johnson(JNJ)Phase 2/3 readout
    AAV5-hRKp.RPGR · Phase 3 · Retinitis Pigmentosa
    NCT05926583: A Study of AAV5-hRKp.RPGR for the Treatment of Japanese Participants With X-linked Retinitis Pigmentosa. Primary completion 2027-06-30 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗

How Johnson & Johnson has moved — past-year price reactions

How binary is JNJ? Its typical daily move, how often it swings ±10%, and its biggest single-day moves over the last year — useful context for sizing around a catalyst.

0.8%
typical day (1Y)
0
±10% days
19%
annualized vol
249
trading days
Largest single-day moves
  • +4%2026-06-26no matched headline
  • -3.7%2026-07-30no matched headline
  • +3.6%2026-07-02no matched headline
  • +3.4%2026-06-23no matched headline
  • +3.3%2026-08-18no matched headline
  • +3.3%2025-12-10no matched headline

Real daily price moves over the past year — not every move is a catalyst, and headlines (where shown) are a possible same-day driver, not confirmed causation.

Johnson & Johnson — active clinical pipeline

Johnson & Johnson's registered Phase 1–3 programs by asset and indication, derived from ClinicalTrials.gov.

77 assets144 programsPh1 40Ph2 36Ph3 64· 4 post-marketing (Ph4)
AreasOncologyAutoimmuneImmunologyNeuroscienceCardiovascularInfectiousOphthalmologyRare / GeneticOther
GuselkumabAutoimmune · IL-12/23
Phase 2
Colitis, UlcerativeCrohn's Disease
Phase 3
Arthritis, PsoriaticCrohn DiseaseCrohn's Disease (2)Crohns DiseaseFistulizing Crohns DiseasePsoriasisUlcerative Colitis
NipocalimabAutoimmune · FcRn
Phase 1
Autoimmune
Phase 2
Myositis
Phase 3
Hemolytic Disease of the Fetus and NewbornLupus Erythematosus, SystemicMyasthenia Gravis (3)Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingSjogrens SyndromeThrombocytopenia, Neonatal Alloimmune (2)
AmivantamabOncology · EGFR/MET
Phase 1
Non-Small-Cell Lung Cancer
Phase 2
Carcinoma, Non-Small-Cell Lung (4)Squamous Cell Carcinoma of Head and Neck
Phase 3
Carcinoma, Non-Small-Cell Lung (2)Colorectal Neoplasms (2)Squamous Cell Carcinoma of Head and Neck
TalquetamabOncology · GPRC5D×CD3
Phase 1
Hematological MalignanciesMultiple MyelomaRelapsed/ Refractory Multiple Myeloma
Phase 2
Hematological MalignanciesMultiple Myeloma (2)
Phase 3
Multiple Myeloma (2)
ApalutamideOncology · AR
Phase 1
Prostatic Neoplasms
Phase 2
Salivary Gland Neoplasms
Phase 3
Metastatic Castrate-sensitive Prostate CancerProstatic Neoplasms
JNJ-79635322Oncology
Phase 1
Multiple MyelomaRelapsed or Refractory Multiple Myeloma
Phase 2
Multiple Myeloma
Phase 3
Multiple Myeloma (2)
PasritamigOncology
Phase 1
Metastatic Castration-resistant Prostate NeoplasmsProstatic Neoplasms
Phase 3
Metastatic Castration-resistant Prostatic NeoplasmsProstatic Neoplasms, Castration-Resistant
TeclistamabOncology · BCMA×CD3
Phase 1
Multiple Myeloma (2)
Phase 2
Hematological Malignancies
Phase 3
Multiple MyelomaRelapsed or Refractory Multiple Myeloma
BleximenibOncology
Phase 1
Leukemia, Myeloid, Acute
Phase 2
Acute Leukemia
Phase 3
Leukemia, Myeloid, Acute
DaratumumabOncology · CD38
Phase 1
Multiple Myeloma
Phase 2
Amyloidosis
Phase 3
Multiple Myeloma (2)
ErdafitinibOncology · FGFR3
Phase 2
Urothelial CancerUrothelial Carcinoma
Phase 3
Urothelial Cancer
Guselkumab Dose 1Autoimmune
Phase 3
Colitis, UlcerativeCrohn DiseaseCrohn's Disease
IbrutinibOncology · BTK
Phase 2
Leukemia, Lymphocytic, Chronic, B-Cell
Phase 3
Chronic Lymphocytic LeukemiaLeukemia, Lymphocytic, Chronic, B-Cell
IcotrokinraAutoimmune
Phase 3
Arthritis, Psoriatic (2)Colitis, UlcerativeCrohn Disease
LazertinibOncology · EGFR
Phase 1
Carcinoma, Non-Small-Cell Lung
Phase 3
Advanced or Metastatic Non-small Cell Lung CancerCarcinoma, Non-Small-Cell Lung
TAR-200Oncology
Phase 2
Urinary Bladder Neoplasms
Phase 3
Bladder CancerNon-Muscle Invasive Bladder Neoplasms
AAV5-hRKp.RPGROphthalmology
Phase 2
X-Linked Retinitis Pigmentosa
Phase 3
Retinitis Pigmentosa
CetrelimabOncology · PD-1
Phase 2
Carcinoma, Non-Small-Cell Lung
Phase 3
Urinary Bladder Neoplasms
Cilta-celOncology
Phase 2
Multiple Myeloma (3)
Phase 3
Multiple Myeloma
JNJ-77242113Autoimmune
Phase 3
Generalized Pustular PsoriasisPlaque Psoriasis (5)
JNJ-78934804Autoimmune
Phase 3
Colitis, UlcerativeCrohn Disease
MilvexianCardiovascular · Factor XIa
Phase 3
Atrial FibrillationIschemic Stroke; Ischemic Attack, Transient
NiraparibOncology · PARP
Phase 1
Prostatic Neoplasms
Phase 3
Castration-Resistant Prostatic Cancer
RamantamigOncology
Phase 2
Multiple Myeloma
Phase 3
Multiple Myeloma
Abiraterone acetate (AA)Oncology
Phase 3
Prostatic Neoplasms
BortezomibOncology · PSMD1
Phase 3
Multiple Myeloma
EsketamineNeuroscience · GRIN1
Phase 3
Depressive Disorder, Major
Esketamine 56 mgNeuroscience · GRIN1
Phase 3
Depressive Disorder, Treatment-Resistant
GemcitabineOncology
Phase 3
Non-Muscle Invasive Bladder Neoplasms
Genetic: AAV5-hRKp.RPGR Intermediate DoseOphthalmology
Phase 3
X-Linked Retinitis Pigmentosa
GolimumabAutoimmune · TNF
Phase 3
Colitis, Ulcerative
Guselkumab SubcutaneousAutoimmune
Phase 3
Colitis, Ulcerative
JNJ-81201887Ophthalmology
Phase 3
Geographic Atrophy
LHRHaOncology
Phase 3
Prostatic Neoplasms
M281Autoimmune · FcRn
Phase 3
Warm Autoimmune Hemolytic Anemia
SeltorexantNeuroscience · OX2R
Phase 3
Depressive Disorder, Major (2)
TAR-210Oncology
Phase 3
Non-Muscle Invasive Bladder Neoplasms
UstekinumabAutoimmune · IL-12/23
Phase 3
Crohn Disease
Amivantamab IVOncology
Phase 2
Advanced or Metastatic Colorectal CancerCarcinoma, Non-Small-Cell Lung
Erdafitinib Intravesical Delivery SystemOncology
Phase 1
Urinary Bladder Neoplasms
Phase 2
Non-Muscle Invasive Bladder Neoplasms
JNJ-95597528Immunology
Phase 2
AsthmaDermatitis, Atopic
CapmatinibOncology · MET
Phase 2
Carcinoma, Non-Small-Cell Lung
DexamethasoneOncology · NR3C1
Phase 2
Carcinoma, Non-Small-Cell Lung
JNJ-101556143Oncology
Phase 2
Prostatic Neoplasms
JNJ-101556143 Formulation 1Oncology
Phase 2
Metastatic Prostate Cancer
JNJ-63723283Oncology · PD-1
Phase 2
Neoplasms
JNJ-64042056Neuroscience
Phase 2
Alzheimer Disease
JNJ-68284528Oncology · BCMA
Phase 2
Multiple Myeloma
JNJ-88545223Autoimmune
Phase 2
Arthritis, Psoriatic
JNJ-90014496Oncology
Phase 2
Lymphoma, Non-Hodgkin
Niraparib 200 mgOncology · PARP
Phase 2
Prostatic Neoplasms, Castration-Resistant
RilpivirineInfectious · HIV RT
Phase 2
Human Immunodeficiency Virus Type 1
14C-bleximenibOncology
Phase 1
Acute Lymphoblastic Leukemia
Ami-LC-MDOncology
Phase 1
Neoplasms
ARX517Oncology
Phase 1
Metastatic Prostate Cancer
AticaprantNeuroscience · κ-opioid
Phase 1
Schizophrenia
JNJ-101684362 (HLD-0117)Oncology
Phase 1
Metastatic Breast Cancer
JNJ-69086420Oncology
Phase 1
Prostatic Neoplasms
JNJ-75348780Oncology
Phase 1
Leukemia, Myeloid, Acute
JNJ-78278343Oncology
Phase 1
Prostatic Neoplasms (3)
JNJ-80948543Oncology
Phase 1
Lymphoma, Non-Hodgkin (2)
JNJ-87562761Oncology
Phase 1
Relapsed or Refractory Multiple Myeloma
JNJ-87801493Oncology
Phase 1
Lymphoma, Non-Hodgkin
JNJ-87890387Oncology
Phase 1
Neoplasms
JNJ-88549968Oncology
Phase 1
Neoplasms
JNJ-88998377Oncology
Phase 1
Lymphoma, Non-Hodgkin
JNJ-89402638Oncology
Phase 1
Colorectal Neoplasms
JNJ-89853413Oncology
Phase 1
Leukemia, Myeloid, Acute
JNJ-89862175Oncology
Phase 1
Advanced-stage Solid Tumors
JNJ-90009530Oncology
Phase 1
Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
JNJ-90189892Oncology
Phase 1
Leukemia, Myeloid, Acute
JNJ-95437446Oncology
Phase 1
Advanced Stage Solid Tumors
JNJ-95566692Oncology
Phase 1
Lymphoma, Non-Hodgkin
JNJ-95804306Oncology
Phase 1
Hematologic Neoplasms
JNJ-98768111Oncology
Phase 1
Prostatic Neoplasms
Teclistamab (IV)Oncology · BCMA×CD3
Phase 1
Hematological Malignancies

Active registered Phase 1–3 trials from ClinicalTrials.gov — not the company's official IR pipeline (no preclinical or undisclosed assets). Grouped by trial intervention name; therapeutic area is auto-categorized. Each indication links to its trial. Molecular targets sourced from ChEMBL (EMBL-EBI).

Targets from a ChEMBL (EMBL-EBI) snapshot dated 2026-08-20 · 310/1701 assets resolved when it was built

See the full biopharma catalyst calendar across all covered companies.